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Aims Obesity has been found to be protective in heart failure (HF), a finding leading to the concept of an obesity paradox.
We hypothesized that a preserved cardiorespiratory fitness in obese HF patients may affect the relationship between
survival and body mass index (BMI) and explain the obesity paradox in HF.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Methods
and results
A total of 4623 systolic HF patients (LVEF 31.5± 9.5%, BMI 26.2± 3.6 kg/m2) were recruited and prospectively
followed in 24 Italian HF centres belonging to the MECKI Score Research Group. Besides full clinical examination,
patients underwent maximal cardiopulmonary exercise test at study enrolment. Median follow-up was 1113
(553–1803) days. The study population was divided according to BMI (<25, 25–30, >30 to ≤35 kg/m2) and predicted
peak oxygen consumption (peak VO2, <50%, 50–80%, >80%). Study endpoints were all-cause and cardiovascular
deaths including urgent cardiac transplant. All-cause and cardiovascular deaths occurred in 951 (28.6%, 57.4 per
person-years) and 802 cases (17.4%, 48.4 per 1000 person-years), respectively. In the high BMI groups, several
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prognostic parameters presented better values [LVEF, peak VO2, ventilation/carbon dioxide slope, renal function,
and haemoglobin (P < 0.01)] compared with the lower BMI groups. Both BMI and peak VO2 were significant
positive predictors of longer survival: both higher BMI and peak VO2 groups showed lower mortality (P < 0.001). At
multivariable analysis and using a matching procedure (age, gender, LVEF, and peak VO2), the protective role of BMI
disappeared.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Conclusion Exercise tolerance affects the relationship between BMI and survival. Cardiorespiratory fitness mitigates the obesity
paradox observed in HF patients.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Keywords Exercise tolerance • Cardiopulmonary exercise testing • Heart failure • Prognosis • Matching
analysis • MECKI score
Introduction
Obesity, commonly defined by increased body mass index (BMI),
has been found to be protective in heart failure (HF), a finding
leading to the accepted concept of an obesity paradox.1–3 This
somewhat surprising evidence has been analysed and studied under
different perspectives in a broad set of HF patients, and it remains
substantially unexplained, with competing and complementary
views being proposed.1–3 It has been suggested that increased
levels of serum lipoproteins play a role by counteracting bacterial
cytokines and endotoxins,4 while low levels of adiponectin5 and a
decreased response to sympathetic activation6 have been associ-
ated with a protective background. Independently of the protective
neuro-hormonal and inflammatory role that an increased BMI may
bear, the multiple interactions between obesity and major clinical
determinants of the natural history of the disease are still under
scrutiny.
Some investigators have suggested that the obesity paradox may
be partly explained by confounding factors.7,8 Cardiorespiratory
fitness is strongly related to prognosis in healthy individuals and in
cohorts with cardiovascular (CV) diseases.9 A number of studies
have reported the importance of exercise capacity and other car-
diopulmonary exercise test (CPET) variables in predicting progno-
sis in HF. Indeed, the classic cut-off point for peak oxygen consump-
tion (peak VO2) of 14mL O2/kg/min proposed by Mancini et al.10
is still frequently used to classify patients with HF into low-risk and
high-risk groups. A strong obesity paradox has also been found in
cohorts of patients with coronary heart disease,11 but it was not
present in those with high levels of exercise tolerance.12 Similar
findings have been more recently reported in systolic HF patients.13
We aimed at further investigating the impact of exercise toler-
ance and cardiorespiratory capacity on the obesity paradox in a
larger cohort of systolic HF patients, using a multicentre database
based on CPET.13
Methods
Population and study procedures
We performed a cohort study on 4843 patients with a history of HF
with reduced LVEF, enrolled and prospectively followed in 24 Italian HF ..
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.. centres. All patients were derived from the MECKI score database, a
database of chronic HF patients that is continuously updated and that
allowed us to validate a new prognostic HF risk model, the Metabolic
Exercise test data combined with Cardiac and Kidney Indexes (MECKI)
score.14 For the present analysis, 220 patients with severe pathological
obesity, as arbitrarily defined by BMI >35, were excluded, reducing the
study cohort to 4623 cases.
At enrolment, inclusion and exclusion criteria were evaluated
as previously reported,14 and clinical history was recorded. Then,
physical examination, laboratory analyses, ECG, and transthoracic
echocardiography were performed, as previously described.14 CPET
was performed, depending on the enrolling centre’s equipment, using a
ramp protocol on an electronically braked cycle-ergometer or a Bruce
modified protocol on a treadmill. Peak VO2 data measured at treadmill
exercise were reduced by 10% to allow an appropriate comparison
between the two different procedures; the CPET protocol was set to
reach peak exercise in 8–12min, but tests were stopped as patients
reported maximal effort, and exercise parameters were calculated
as previously described.14 Peak VO2 % of predicted was calculated
according to Hansen et al.15
Follow-up and study endpoints
Follow-up was carried out according to the local HF programme, and
it ended with the last clinical evaluation or with the patients’ death or
heart transplantation. If a patient died outside the hospital where they
were being followed up, medical records of the event and a report of
the cause of death were considered. The primary study endpoint was
all-cause death (total mortality) and CV deaths. Urgent cardiac trans-
plant was considered as death both for total and CV mortality. Proce-
dures of data management were performed as previously described.14
Data analysis
Data analysis was performed in two steps. The first part of the
analysis considered the entire population (4623 patients), which was
divided into four groups according to BMI: <25, 25–30, >30 to ≤35,
and >35 kg/m2. Subsequently, to assess the role of cardiopulmonary
capacity on survival, the study population was also divided into three
subgroups according to predicted peak VO2 (<50, 50–80, and >80%).
Demographic, laboratory, echocardiographic, CPET, and follow-up data
were compared between groups, and Cox univariable and multivariable
regression analysis and Kaplan–Meier survival analysis were performed
for the previously described study endpoints (CV mortality and total
mortality). Kaplan–Meier analysis was arbitrarily truncated at 3 years.
© 2016 The Authors
European Journal of Heart Failure © 2016 European Society of Cardiology
Exercise tolerance can explain the obesity paradox in heart failure 547
In the second step, as a confirmation of the first analysis, we per-
formed a 1:1:1 statistical matching between the three BMI classes. A
total of 628 patients per group matched for the following arbitrarily
selected variables: age± 5 years, gender, LVEF± 5, and peak VO2 ±150
(mL/min). Kaplan–Meier survival analysis was then repeated as previ-
ously described.
A further analysis of the BMI <25 group, differentiating BMI <18.5
and 18.5–25 groups, was also performed; however, since the percent-
age of patients with BMI <18.5 was very limited (<2%), and thus not
comparable with the other groups, no further statistical evaluation was
performed (the analysis is presented as Supplementary material online,
Tables and Figure S1).
Statistical analysis
Numerical variables were summarized as mean± standard devia-
tion. Analysis of variance (ANOVA) was used when appropriate for
between-group comparison. Skewed data are reported as median and
interquartile range and compared by Kruskall–Wallis test. Categorical
variables, expressed as percentage or frequency, were compared by
휒2 test. Bonferroni correction was employed to account for multiple
comparisons.
Two multivariable Cox proportional hazard models were used for
assessing the independent prognostic value of BMI: the first one
adjusted for class of VO2 % of predicted, and the second one for peak
VO2 (absolute value), age, gender, and LVEF.
Moreover, in order to reduce the presence of confounding factors
that could have affected the comparison, BMI groups were matched
according to gender, age, LVEF, and peak VO2. Survival was estimated
by Kaplan–Meier analysis and compared by log-rank test. Unadjusted
hazard ratios and 95% confidence intervals were calculated. A P-value
<0.05 was used to define statistical significance. All analyses were
performed using the SAS 9.2 statistical package.
Results
Mean age of the study population was 61.6±12.6 years, 17.2%
were female, average BMI was 26.2± 3.6 kg/m2, LVEF 32.8± 7.7%,
and peak VO2 1129± 416mL/min. Regarding therapy, 93.7% were
on ACE inhibitors or ARBs, 80.8% on beta-blockers, while 51.0%
were on a mineralocorticoid antagonist. Median follow-up was
1113 (553–1803) days; 6.8% of patients were tested with a tread-
mill and 93.2% with cycle-ergometer. Exercise effort was, on aver-
age, maximal or nearly maximal in all groups from a metabolic
point of view, as shown by the peak exercise respiratory exchange
ratio (RER; Table 1). Total and CV mortality occurred in 28.6%
and 17.4%, respectively, of the entire study population, includ-
ing, in both cases, urgent cardiac transplant, which occurred in
110 cases.
Body mass index groups
Grouping patients according to BMI <25, between 25 and 30,
and between 30 and 35 showed that patients presented different
clinical characteristics (Table 1a). The highest BMI group patients
were younger, with more favourable LVEF, peak VO2, ventilation vs.
carbon dioxide production slope, renal function, and haemoglobin
level. They had a larger use of beta-blockers (Table 1a). ..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
Total mortality
1.00
0.98
0.96
0.94
0.92
0.90
S
ur
vi
va
l
S
ur
vi
va
l
0.88
0.86
0.84
0.82
0.80
1.00
0.98
0.96
0.94
0.92
0.90
0.88
0.86
0.84
0.82
0.80
0.0 0.5
BMI<25 BMI≥25–30
Cardiovascular death
BMI>30≤35
p<0.001
p<0.001
1.0 1.5 2.0 2.5 3.0
(Years)
0.0 0.5 1.0 1.5 2.0 2.5 3.0
(Years)
Figure 1 Survival analysis in the entire study population
(n= 4623) grouped according to body mass index (BMI). The
Kaplan–Meier curves were truncated at 3 years. Upper panel:
total mortality+ urgent cardiac transplant. Lower panel: car-
diovascular death+ urgent cardiac transplant. P< 0.001 in both
cases.
Body mass index was a significant predictor of both total and
CV death, and the highest mortality rate occurred in the lowest
BMI group (<25) (P< 0.001) (Figure 1; Table 1b). Even separately
analysing underweight patients (BMI <18.5) in the <25 BMI group,
the results did not differ, i.e. the detrimental effects of the leaner
condition were confirmed.
Interestingly, the very severely obese subjects (BMI >35),
although they had more favourable clinical characteristics than the
less obese (younger age, higher peak VO2, see Table 1a), presented
an intermediate mortality between BMI 25–30 and BMI >30 to
≤35 groups (Table 1b).
Predicted peak oxygen consumption
groups
Peak VO2 was a significant predictor of mortality: patients with
predicted peak VO2 < 50% (n=1908) presented a worse survival
than those with predicted peak VO2 ranging from 50% to 80%
(n= 2363) and those with predicted peak VO2 > 80% (n= 352), for
both total and CV deaths (Table 2).
As patients were grouped for peak VO2, BMI did not affect
survival (Table 3).
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Table 2 Mortality in the heart failure population grouped according to peak oxygen consumption
VO2 < 50%
(n= 1908)
VO2 50–80%
(n= 2363)
VO2 > 80%
(n= 352)
P-value Post-hoc by Bonferroni
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
n % n % n % VO2 < 50% vs.
VO2 50–80%
VO2 < 50% vs.
VO2 > 80%
VO2 50–80%
vs. VO2 > 80%. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Total mortality (absolute) 596 31.3 341 14.4 14 4.0 <0.001 <0.001 <0.001 <0.001
Total mortality (1000 person-years) 89.8 39.0 11.8 <0.001* <0.001 <0.001 <0.001
Cardiovascular mortality (absolute) 518 27.2 274 11.7 10 2.8 <0.001 <0.001 <0.001 <0.001
Cardiovascular mortality (1000 person-years) 78.1 31.4 8.5 <0.001* <0.001 <0.001 <0.001
VO2, oxygen consumption.
*P calculated by 휒2 except for incidence of mortality calculated by log rank test.
Table 3 Mortality in the three peak oxygen consumption groups according to body mass index
n No. of events
total mortality
% 1000 person-
years
No. of events
cardiovascular
mortality
% 1000 person-
years
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
VO2 < 50% (n=1944) Low BMI <25 980 336 34.3 94.5 296 30.3 83.3
Medium BMI 25–30 735 209 28.4* 86.0 179 24.4* 73.7
High BMI >30 to ≤35 193 51 26.4 78.4 43 22.3 66.1
Very high BMI >35 36 16 44.4 137.2 13 36.1 111.5
Global 596 31.3 89.8 518 27.2 78.1
P-value 0.007 NS 0.008 NS
VO2 50–80% (n= 2496) Low BMI <25 717 97 13.6 38.7 75 10.5 29.9
Medium BMI 25–30 1176 178 15.2 39.1 148 12.6 32.5
High BMI >30 to ≤35 470 66 14.0 39.3 51 10.9 30.4
Very high BMI >35 133 24 18.0 51.2 20 15.2 42.7
Global 341 14.4 39.0 274 11.7 31.4
P-value NS NS NS NS
VO2 > 80% (n= 403) Low BMI <25 68 3 4.4 12.9 3 4.4 12.9
Medium BMI 25–30 176 6 3.4 10.2 5 2.8 8.5
High BMI >30 to ≤35 108 5 4.6 13.9 2 1.9 5.6
Very high BMI >35 51 1 2 6.3 1 2 6.3
Global 14 4.0 11.8 10 2.8 8.5
P-value NS NS NS NS
Total 4843 951 19.7 57.4 802 16.6 48.4
*P <0.05 vs. BMI <25 at Bonferroni post-hoc test.
BMI, body mass index; VO2, oxygen consumption.
At univariable analysis, both BMI and peak VO2, as absolute
values and predicted values, were associated with prognosis. Cox
analysis showed that BMI class adjusted for peak VO2 % of the
predicted value (class) or by age, gender, LVEF, and peak VO2
(absolute value) lost its prognostic capacity considering either total
or CV death (Table 4).
When patients of the three BMI groups were matched according
to age, gender, LVEF, and peak VO2 absolute value, 628 triplets of
matched subjects were obtained (Table 5). No significantly different
prognosis was observed for both total and CV death, regardless of
the BMI group (Figure 2). It is of note that patients with BMI >35
were not included in the matching analysis due to the low sample
size (n= 220). ..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.. Discussion
This study aimed at investigating the role of cardiorespiratory
fitness in the prognosis of obese HF patients in a large cohort
of stable patients undergoing CPET. Some important observations
can be made. First, the obesity paradox in patients with systolic HF
was also confirmed in the present group of patients referred for
CPET. Secondly, the important role of cardiopulmonary exercise
capacity in the prognosis of patients with systolic HF receives
further confirmation. Thirdly, and most importantly, the prognostic
contribution of peak VO2 overwhelms the prognostic capacity of
BMI. Furthermore, the prognostic role of BMI disappears if more
variables are considered, such as age, gender, LVEF, and peak VO2.
Consequently, high BMI patients have a better prognosis compared
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Table 4 Mortality according to body mass index and peak oxygen consumption
P-value Hazard ratio 95% CI
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
CV mortality
BMI class unadjusted <0.001 0.771 0.696–0.855
VO2 % class unadjusted <0.001 0.388 0.34–0.444
VO2 peak unadjusted (mL/min) <0.001 0.998 0.998–0.999
BMI class adjusted by VO2 % class 0.3119 0.947 0.853–1.052
BMI class adjusted by VO2 peak, age, gender, LVEF 0.1983 1.067 0.967–1.177
Total mortality
BMI class unadjusted <0.001 0.804 0.732 0.884
VO2 % class unadjusted <0.001 0.42 0.372 0.475
VO2 peak unadjusted (mL/min) <0.001 0.999 0.998 0.999
BMI class adjusted by VO2 % class 0.5701 0.973 0.884 1.07
BMI class adjusted by VO2 peak, age, gender, LVEF 0.1983 1.067 0.967 1.177
BMI, body mass index; CV, cardiovascular; VO2, oxygen consumption.
Table 5 Age, gender, left ventricular ejection fraction, and peak oxygen consumption in heart failure patients used for
matching analysis
BMI <25 (n= 628) BMI ≥25–30 (n= 628) BMI >30 to ≤35 (n= 628)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age (years) 59.1± 12.8 59.9±11.8 59.8±11.7
Gender (M/F) (556/72) 556/72 556/72
LVEF (%) 32.8± 9.1 32.7± 9.4 32.7± 9.2
Peak VO2 (mL/min) 1227± 401 1240± 395 1242± 394
BMI, body mass index; F, females; M, males; VO2, oxygen consumption.
with slimmer patients. However, obese groups presented a less
advanced HF condition, as indicated by the presence of several
more favourable prognostic indicators; they were better treated,
and they presented a more preserved exercise tolerance.
Obese subjects are significantly represented in both the
general and HF population. In the present cohort of HF
patients able to perform a CPET, 16.3% of patients had a
BMI ranging between 30 and 35. Notably, we excluded from the
present analysis 220 patients with extreme obesity (BMI >35),
which account for 4.5% of the overall cohort of HF patients
in the MECKI score database, because extreme obesity is a
pathological status associated with several possible conditions,
besides HF, which affect exercise capacity, including orthopaedic
reasons—the work of lifting up the increased body weight, par-
ticularly on a treadmill—and mechanical difficulties in performing
exercise.
However, a number of studies have now found that overweight
and obese patients with HF have a better prognosis than normal
weight or underweight HF patients.1–4 Also in our cohort of HF
patients, high BMI patients have a better prognosis (Figure 1). Many
investigators have suggested that the obesity paradox may at least
partly be explained by confounding factors.6 In cohorts with CAD,
patients with high levels of exercise capacity did not seem to have
an obesity paradox.7,8 On the other hand, in higher risk patients
with CAD and low levels of exercise tolerance, a strong obesity
paradox was present, with overweight and obese individuals having .
..
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..
..
..
..
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..
.. a better prognosis than their lean counterparts with low exercise
tolerance.7–9
In HF, there is not only an ‘obesity paradox’: higher levels of
blood pressure and cholesterol are also associated with a better
prognosis.16
In the present study, we evaluated a large database of HF
patients with—on average—mild LV systolic dysfunction, all of
which underwent an exercise test, aiming at further investigating
the role of obesity in this population. We specifically investigated
the role of exercise capacity vs. BMI. First of all, on average, the
exercise effort performed by the patients was relevant, nearly
maximal, as documented by the high RER reached at peak exercise
in all BMI groups (Table 1a).17 If anything, a lower RER value
was observed in the 30–35 BMI group that had the highest
exercise performance. Secondly, we observed that peak VO2
maintains its prognostic value in all BMI groups, confirming the
pivotal role of exercise evaluation in HF patients regardless of
BMI. Thirdly, when peak VO2 is considered as a covariate in the
survival analysis, the so-called ‘obesity paradox’ is lost. Regardless
of whether the different BMI populations were normalized for
peak VO2, either expressed as absolute value or as a percentage
of the predicted value, prognostic differences between the BMI
classes were lost. Indeed, we observed that BMI distinguished, in
the HF population, patients with different clinical characteristics
and different prognosis. Specifically, those with a higher BMI all
presented better prognostic parameters, were better treated, and
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Figure 2 Survival analysis according to body mass index (BMI) in the 628 patients matched for age, gender, peak oxygen consumption, and
LVEF. Upper panel: total mortality+ urgent cardiac transplant. Lower panel: cardiovascular death+ urgent cardiac transplant. Differences were
not significant.
showed a longer survival. It is unclear why patients with high BMI
and low peak VO2 were not enrolled in this database derived from
the MECKI Score Research Group. It is of note that this is probably
the largest HF population analysed with CPET. However, because
all patients who met the MECKI score criteria were analysed,
it is possible that referring physicians were reluctant to request
and/or perform an exercise evaluation in obese subjects with
severe HF.
To confirm the Cox analysis, we also performed a matching
procedure considering, on top of peak VO2 (absolute value), age,
gender, and LVEF. We were able to identify a relevant number
of triplets of cases (n= 628) to be considered for the three BMI
classes. Obese HF subjects matched for peak VO2, age, gender, and
LVEF have a similar prognosis to that of HF patients with BMI <25 .
..
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..
..
..
. or between 25 and 30. This confirms that the ‘obesity paradox’ in
HF is due to a patient selection bias.
The results presented here are consistent with recent studies
performed in smaller populations of advanced systolic HF patients,
showing that the obesity paradox was only observed in patients
with lower cardiorespiratory fitness.13,18 Consequently, this find-
ing supports the superior prognostic power of improved functional
capacity and the importance of physical conditioning that attenu-
ates the obesity paradox.
Progressive declines in physical activity over five decades have
occurred and have primarily caused the obesity epidemic. In light
of the obesity paradox, the potential value of purposeful weight
loss and increased physical activity to affect levels of fitness should
be underlined.19
© 2016 The Authors
European Journal of Heart Failure © 2016 European Society of Cardiology
552 M.F. Piepoli et al.
Exercise training is not the single intervention that increases
peak VO2 and survival, but there is evidence that cornerstone
therapies such as ACE inhibitors and ARBs improve not only LV
systolic function, and prognosis, but also exercise capacity (peak
VO2).20,21 Also long-term beta-blocker therapy increases exercise
time and improves ventilator response to exercise, and therefore
patients are less symptomatic for a given ventilation during exercise
following beta-blocker treatment.22,23
Study limitations
Some limitations of the MECKI score database have already been
discussed.14,24 The patients were relatively young; mean age was
62 years, probably reflecting the inclusion of patients referred for
CPET. Only 15% of the patients were females; pathophysiological
and clinical gender-related differences have been found in HF.
Only HF patients with reduced LVEF were included; thus, the
results cannot be extrapolated to patients with preserved EF.
Moreover, we evaluated patients able to perform a CPET, so
that patients with very severe HF were excluded. Therefore, our
findings should not be considered when evaluating patients with
the above-reported characteristics. We focused on peak VO2
instead of other CPET-derived prognostic variables, because peak
VO2 is the most widely used measure of exercise capacity in
HF. Further studies addressing the influence of BMI on VE/VCO2
would be of interest. Finally, the obese subjects presented a RER
without a statistically significant difference with respect to the
other BMI groups (1.08± 0.12 vs. 1.11± 0.12 high vs. medium
BMI). Accordingly exercise intensity differences, due to patients
effort, are unlikely to have any clinical relevance.
Conclusion
In practical terms, these results suggest that exercise tolerance
affects the relationship between BMI and survival. Thus, the obesity
paradox in systolic HF is due to a patient selection bias and, at least
in the present population, it does not exist. Consequently, assessing
obese subjects without considering their exercise capacity, as
assessed by CPET, may be misleading.
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